A phase II trial of bryostatin-I administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

Abstract

Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia.

Metadata

Item Type:	Article
Authors/Creators:	Clamp, A.R. Blackhall, F. Vasey, P. Soukop, M. Coleman, R. https://orcid.org/0000-0002-4275-1043 Halbert, G. Robson, L. Jayson, G.C. Canc Res UK Phase I II Comm
Copyright, Publisher and Additional Information:	© 2003 Cancer Research UK. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
Keywords:	bryostatin-1; ovarian cancer; protein kinase C; clinical trial;
Dates:	Accepted: 24 July 2003 Published (online): 30 September 2003 Published: 6 October 2003
Institution:	The University of Sheffield
Academic Units:	The University of Sheffield > Sheffield Teaching Hospitals
Depositing User:	Symplectic Sheffield
Date Deposited:	29 Jan 2021 17:45
Last Modified:	29 Jan 2021 17:45
Status:	Published
Publisher:	Springer Nature
Refereed:	Yes
Identification Number:	10.1038/sj.bjc.6601285
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:170596

CORE (COnnecting REpositories)

A phase II trial of bryostatin-I administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

Abstract

Metadata

Download

Published Version

Export

Statistics